Boston Scientific Corporation BSX

43.92 (0.76) (1.70%) as of 25 Sep
Market cap
$64.7B
P/E
17.7×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month

Boston Scientific Corporation (BSX) Net margin

Boston Scientific Corporation's net margin over the twelve months to 30 June 2026 was 17.5%, up 3.1 percentage points from fiscal 2025 (14.4%). Over the past ten years it has ranged from −3.20% (fiscal 2015) to 43.8% (fiscal 2019); the current reading is higher than 82% of that period. That is above the Medical Devices industry median of −20.4% and above the Healthcare sector median of 0.00%.

Net margin, annual

Annual

Period Net margin Change (points)
FY2025 14.4% 3.38
FY2024 11.1% 0.03
FY2023 11.0% 5.97
FY2022 5.06% (3.23)
FY2021 8.29% 9.45
FY2020 −1.16% (44.94)
FY2019 43.8% 26.77
FY2018 17.0% 15.86
FY2017 1.15% (2.99)
FY2016 4.14% 7.34

Quarterly

Period Net margin Change (points)
Jun 2026 16.7% (9.10)
Mar 2026 25.8% 13.05
Dec 2025 12.7% (2.19)
Sep 2025 14.9% (0.84)
42 more quarters

Against its own ten years

Low −3.20% High 43.8%
Ten-year median 8.29%
Current reading's percentile 82

Net margin against peers

Company Net margin
DXCM DexCom, Inc. compare 20.1%
BSX Boston Scientific Corporation 17.5%
EW Edwards Lifesciences Corporation compare 15.4%
SYK Stryker Corporation compare 14.4%
MDT Medtronic PLC compare 13.9%
STE STERIS plc compare 13.3%
ABT Abbott Laboratories compare 11.7%
GEHC GE HealthCare Technologies Inc. compare 9.33%
PHG Koninklijke Philips N.V. compare 6.24%
Medical Devices industry median −20.4%
Healthcare sector median 0.00%
Market median 0.55%

What Net margin is

Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.

Net Income Allotted to Shareholders ÷ Revenue

The full definition of Net margin →

More on BSX